Training in HIV Genomics, Treatment, and Cure Research in Botswana
博茨瓦纳的艾滋病毒基因组学、治疗和治愈研究培训
基本信息
- 批准号:10688707
- 负责人:
- 金额:$ 30.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcquired Immunodeficiency SyndromeAdultAdvisory CommitteesAfricaAfricanAnti-Retroviral AgentsAreaBotswanaClinicalClinical TrialsDoctor of PhilosophyEnvironmentEpidemicFacultyFundingGenomicsGoalsHIVHIV/AIDSHealthHigh PrevalenceInfrastructureInternationalJournalsLaboratoriesLaboratory ResearchMentorsMonitorPatientsPerformancePharmacotherapyPhysiciansPositioning AttributePostdoctoral FellowPublic Health SchoolsPublicationsResearchResearch ActivityResearch DesignResearch PersonnelResearch TrainingResistanceSARS-CoV-2 variantSiteTeacher Professional DevelopmentTechniquesTrainingTraining ProgramsTraining SupportUniversitiesWorkexperiencefaculty mentorpre-doctoralprogramssuccesstraining opportunitytreatment programtreatment research
项目摘要
PROJECT ABSTRACT
The goal of this proposal is to provide research training in HIV genomic, treatment, and cure research at the
Botswana-Harvard AIDS Institute Partnership (BHP), building on advances in laboratory research and clinical
trial infrastructure at BHP that support training opportunities in the most advanced HIV laboratory techniques
and study designs in the region. The environment at BHP offers a host of research opportunities for trained
researchers in Botswana, matching current research activities of the faculty mentors and key partners working
at the Botswana site. BHP is a partnership is between the Harvard TH Chan School of Public Health and the
Ministry of Health (MOH) in Botswana (and the University of Botswana), and the largest HIV/AIDS research
organization in Botswana (and one of the largest in Africa). The long-term goals and objectives of this Fogarty
training program are to continue training research leaders who can take responsibility for BHP within the next
5–10 years, and researchers who can become academic faculty at the University of Botswana (UB) and HIV
experts at MOH. Botswana currently has the third-highest prevalence of HIV in the world for adults (21%), but
has also had the highest rate of antiretroviral drug treatment (ART) for patients with HIV (over 90%), and BHP
has led efforts to support the treatment program with cutting-edge research in resistance and other genomic
work, supported by Fogarty trainees. This work is now extending into the realm of HIV cure research, and into
the intersection between HIV and SARS-CoV-2; BHP is now an internationally recognized center for research
to understand the relationship between new SARS-CoV-2 variant emergence and the HIV epidemic. The
training faculty at Harvard and at BHP will focus their ongoing efforts on keeping Fogarty trainees at the
forefront of genomics, treatment, and cure research and strengthening training opportunities that are not
available elsewhere in the region. We have requested funds for 2 predoctoral and 3 postdoctoral positions
each year. We estimate that we will train about 18 trainees over 5 years, allowing for multiple years for each
PhD candidate and some postdoctoral fellows, and assuming several short-term trainees could fill a single
annual training slot. Stipends will be based on current degrees and research experience. All trainees would
have at least a BSc degree. We estimate that about half will be physicians with clinical experience. Some will
be postdoctoral fellows who have PhD’s in a related area but no experience in HIV research. Each trainee will
have a primary mentor. Selection of trainees is based on previous academic performance, references,
experience, and assurance that the candidates will return to participate in HIV research in Botswana. The
quality of the program will be monitored by a Training Advisory Committee composed of experts from the US
and the southern African region. The success of the training program will be judged by the implementation of
successful treatment research programs that involve trainees, numbers of trainee publications in high-impact
journals, and relative increase in senior research positions at BHP, UB, and MOH held by former trainees.
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHAHIN LOCKMAN其他文献
SHAHIN LOCKMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHAHIN LOCKMAN', 18)}}的其他基金
Addressing Major HIV Prevention and Health Outcomes Questions in an Era of Universal ART: Mentoring in a Community-Randomized Trial
解决普遍抗逆转录病毒治疗时代的主要艾滋病毒预防和健康结果问题:社区随机试验中的指导
- 批准号:
10112810 - 财政年份:2017
- 资助金额:
$ 30.44万 - 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
- 批准号:
10483694 - 财政年份:2017
- 资助金额:
$ 30.44万 - 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
- 批准号:
10669765 - 财政年份:2017
- 资助金额:
$ 30.44万 - 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
- 批准号:
9073896 - 财政年份:2015
- 资助金额:
$ 30.44万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
9975952 - 财政年份:2013
- 资助金额:
$ 30.44万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10396618 - 财政年份:2013
- 资助金额:
$ 30.44万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10161878 - 财政年份:2013
- 资助金额:
$ 30.44万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10462051 - 财政年份:2013
- 资助金额:
$ 30.44万 - 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
- 批准号:
8316378 - 财政年份:2010
- 资助金额:
$ 30.44万 - 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
- 批准号:
8144267 - 财政年份:2010
- 资助金额:
$ 30.44万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 30.44万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 30.44万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 30.44万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 30.44万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 30.44万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 30.44万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 30.44万 - 项目类别: